Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

The Guardian - UK

Bryan Johnson Spent Millions To Be 18 Again—Says Novo Nordisk's Ozempic Anti-Aging Hype Is Misleading: 'Data Is Not There'

Tech entrepreneur Bryan Johnson, who spends $2 million annually on anti-aging treatments, refutes claims that Novo Nordisk AS‘s (NYSE:NVO) Ozempic demonstrates anti-aging properties. Johnson disputed a post on social platform X suggesting the diabetes drug reverses biological aging by 3.1 years.

Benzinga

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic could be hurting your gym gains — with potentially dangerous consequences

The Independent UK

OPINION - The real problem with Ozempic? The hell that comes after

It’s not actually that hard to imagine. Have you been on a diet? Have you ever lost weight? If so, the chances are you put that weight right back on again. I’ve done it. Oprah’s done it. Sam Smith have done it. My cat did it (RIP, my boy).

Evening Standard

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

Barchart

Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

MarketBeat

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.

Benzinga

Companies explore other uses for popular weight loss injections

IN FULL

The Independent UK

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Barchart

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Benzinga

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

Shares of Novo Nordisk A/S (NYSE:NVO) are trading lower Wednesday morning, extending a dramatic sell-off from Tuesday’s session. Here’s what investors need to know.

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Kiplinger

UnitedHealth Stock Drags on Dow: Stock Market Today

Corporate earnings have dominated Wall Street's attention this week, but that changes on Wednesday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

International Business Times

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

Evening Standard

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Euronews

Novo Nordisk shares plummet over 20% on weight-loss drug sale slump

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.

Benzinga

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk A/S (NYSE:NVO) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and appointing a new CEO.

Barchart

Here’s What Happened the Last Time Novo Nordisk Stock Was This Oversold

NVO stock is plunging lower in premarket trading after slashing its guidance for 2025 again.

The Guardian - UK

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.